S
FHTX icon

SignatureFD’s Foghorn Therapeutics FHTX Stock Holding History

SignatureFD’s Portfolio FHTX Stock Details FHTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-45
Closed -$1K – 3171
2022
Q2 		$1K Sell
45
-139
-76% -$1.79K ﹤0.01% 2907
2022
Q1 		$3K Buy
+184
New +$2.52K ﹤0.01% 2670
2021
Q3 		– Sell
-76
Closed -$1K – 3092
2021
Q2 		$1K Buy
+76
New +$828 ﹤0.01% 2718

Other funds holding FHTX

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
EC
Euclidean Capital New York $392M AUM 31.85% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

SignatureFD's FHTX Position: Q3 2022 in Review

SignatureFD sold out of Foghorn Therapeutics (FHTX) in Q3 2022, closing a stake of 45 shares — an estimated $1K sold.

SignatureFD first reported a position in FHTX in Q2 2021 and held it in 3 quarters. The position peaked at $3K in Q1 2022. 62 funds tracked by Wall St. Rank hold FHTX as of Q3 2022.

  • SignatureFD reported no remaining Foghorn Therapeutics position as of Q3 2022 after selling out during the quarter.
  • SignatureFD sold 45 Foghorn Therapeutics shares in Q3 2022, an estimated $1K.
  • SignatureFD first reported a position in Foghorn Therapeutics in Q2 2021 and held it in 3 quarters.
  • SignatureFD's Foghorn Therapeutics position peaked at $3K in Q1 2022.
  • 62 funds tracked by Wall St. Rank held Foghorn Therapeutics as of Q3 2022.

Based on SignatureFD's 13F filing for Q3 2022, filed 8 Nov 2022.